Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

STOCKWATCH: Alien invasions and base behavior in genomics

This article was originally published in Scrip

Executive Summary

In the past few days it has become clear that the original $118 million bid for Californian genome sequencing firm Complete Genomics by China's BGI-Shenzhen was trumped by a $124 million bid from another US sequencing technology company Illumina. The higher bid was subsequently rejected by the Complete Genomics board, possibly because the company did not want to risk the use of a $30 million bridging loan that followed the signing of the merger agreement. Complete Genomics has argued in its SEC filings that the unsolicited offer from Illumina did not constitute ‘a Superior Proposal’ to BGI’s offer despite being worth 5% more because “among other reasons, there is a substantial likelihood that any transaction […] would fail to receive antitrust clearance.”

You may also be interested in...



Stockwatch: Hopes For Fireworks But Expectations For Goldilocks

With the 38th J.P. Morgan Healthcare conference about to start in San Francisco, expectations in the investment community are naturally high. This is after a year when the NASDAQ Biotech Index approached its 2015 all-time high, fueled by the acquisitions of biotech companies by pharma companies.

Time Is Money: Is There A Better Way To Value Asset Duration In Biopharma Deal-Making?

Time is the least considered driver of asset valuations in life sciences – and may be a factor behind the low level of M&A deals so far this year. ICON’s Andy Smith provides some advice to the C-suite and business development managers on strategies to clarify the duration aspect in risk-sensitive transaction negotiations.

Stockwatch: Alexion, United Therapeutics, Intercept And "Alternative Facts"

Mid-cap biotech companies Alexion and United Therapeutics both missed fourth-quarter sales expectations and although Intercept beat analysts' estimates with $13.4m in sales, does that justify a $3bn valuation?

Topics

Related Companies

UsernamePublicRestriction

Register

SC019633

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel